| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/10/2002 | CA2414690A1 Anthelmintics for preventing parasitic infections in humans and animals |
| 01/10/2002 | CA2414660A1 Use of galiella lactone |
| 01/10/2002 | CA2414650A1 Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery |
| 01/10/2002 | CA2414468A1 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| 01/10/2002 | CA2414464A1 Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| 01/10/2002 | CA2414461A1 Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| 01/10/2002 | CA2414446A1 Ruthenium (ii) compounds for use in the therapy of cancer |
| 01/10/2002 | CA2414355A1 Amphipathic linear peptides and compositions containing same |
| 01/10/2002 | CA2414352A1 Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies |
| 01/10/2002 | CA2414347A1 Vaccine comprising active agent immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide |
| 01/10/2002 | CA2413802A1 Substituted-triazolopyrimidines as anticancer agents |
| 01/10/2002 | CA2413756A1 Dna encoding human serine protease d-g |
| 01/10/2002 | CA2413245A1 N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity |
| 01/10/2002 | CA2413243A1 Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders |
| 01/10/2002 | CA2413166A1 Acid-modified arabinogalactan protein composition |
| 01/10/2002 | CA2413158A1 Ecm-related tumor marker |
| 01/10/2002 | CA2412874A1 Pyrones as inhibitors of cyclooxygenase-2 |
| 01/10/2002 | CA2412845A1 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents |
| 01/10/2002 | CA2412839A1 Use of secretin-receptor ligands in treatment of cystic fibrosis (cf) and chronic obstructive pulmonary disease (copd) |
| 01/10/2002 | CA2412830A1 Antibacterial method and composition with phenolic compounds |
| 01/10/2002 | CA2412676A1 Anti-viral composition |
| 01/10/2002 | CA2412620A1 Vitamin k and essential fatty acids |
| 01/10/2002 | CA2412292A1 Base analogues |
| 01/10/2002 | CA2412287A1 Tetrahydropyridino or piperidino heterocyclic derivatives |
| 01/10/2002 | CA2412270A1 Pyrrole derivatives for treating aids |
| 01/10/2002 | CA2411864A1 Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv) |
| 01/10/2002 | CA2411692A1 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| 01/10/2002 | CA2411386A1 Combination therapy for treatment of psychoses |
| 01/10/2002 | CA2410972A1 Compounds to treat alzheimer's disease |
| 01/10/2002 | CA2410945A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| 01/10/2002 | CA2410680A1 Compounds to treat alzheimer's disease |
| 01/10/2002 | CA2410658A1 Pyrroloquinolones as antiviral agents |
| 01/10/2002 | CA2410651A1 Compounds to treat alzheimer's disease |
| 01/10/2002 | CA2410476A1 Method for treatment and prevention of mastitis |
| 01/10/2002 | CA2406649A1 B7-like polynucleotides, polypeptides, and antibodies |
| 01/09/2002 | EP1170594A2 Methods for the identification of compounds useful for the treatment of disease states mediated by Prostaglandin D2 |
| 01/09/2002 | EP1170588A1 A method of testing the purity or stability of 'lamotrigine' with the use of a 1,2,4-triazine derivative as reference marker |
| 01/09/2002 | EP1170368A2 Immunization by inoculation of dna transcription unit |
| 01/09/2002 | EP1170289A2 Retroviral protease inhibiting compounds |
| 01/09/2002 | EP1170288A2 Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists |
| 01/09/2002 | EP1170286A1 Prostaglandin e1 derivatives |
| 01/09/2002 | EP1170281A1 1,1- and 1,2-disubstituted cyclopropanes, process for their preparation and pharmaceutical compositions thereof |
| 01/09/2002 | EP1170020A1 Patches for external use |
| 01/09/2002 | EP1170017A1 Use of tumor necrosis factor alpha (TNF-alpha) and vascular endothelial growth factor (VEGF) for the manufacture of a therapeutic composition |
| 01/09/2002 | EP1170014A1 Proteoglycan, a bioactive substance from plants |
| 01/09/2002 | EP1170012A1 Cerebrovascular regeneration/reconstruction promoters and nerve tissue secondary degeneration inhibitors comprising ginsenoside rb 1? |
| 01/09/2002 | EP1170011A1 Novel use of inhibitors of the epidermal growth factor receptor |
| 01/09/2002 | EP1170010A2 Method of using (+) cisapride for the treatment of gastro-esophageal reflux disease and other disorders |
| 01/09/2002 | EP1170009A2 Thiazolybenzofuran derivatives and their use as SRS-A and leukotiene antagonists |
| 01/09/2002 | EP1170008A1 Valproic acid and derivatives thereof as histone deacetylase inhibitors |
| 01/09/2002 | EP1170007A1 Remedies |
| 01/09/2002 | EP1170006A1 Drugs for relieving hemicrania |
| 01/09/2002 | EP1170005A1 Autonomic controlling agents |
| 01/09/2002 | EP1169644A1 Method to type prion proteins |
| 01/09/2002 | EP1169475A1 Diagnosis of a person's risk for developing atherosclerosis or diabetic retinopathy |
| 01/09/2002 | EP1169469A1 Human colon cancer associated gene sequences and polypeptides |
| 01/09/2002 | EP1169445A2 Human proteins and polynucleotides encoding them |
| 01/09/2002 | EP1169444A2 Compositions and methods for the treatment and diagnosis of breast cancer |
| 01/09/2002 | EP1169442A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/09/2002 | EP1169441A2 Treatment of cardiac power failure using s100 proteins |
| 01/09/2002 | EP1169350A2 Human obesity protein binding protein-2 homolog compositions and uses thereof |
| 01/09/2002 | EP1169347A2 Compounds and methods for therapy and diagnosis of lung cancer |
| 01/09/2002 | EP1169345A2 Genes associated with diseases of the kidney |
| 01/09/2002 | EP1169342A2 Tuberculosis antigens and methods of use therefor |
| 01/09/2002 | EP1169339A1 Macrocyclic peptides inhibiting the hepatitis c virus ns3 protease |
| 01/09/2002 | EP1169337A2 Steroid nitrates for the treatment of oxidative injury and endothelial dysfunction |
| 01/09/2002 | EP1169336A1 Ent-steroids as selectively active estrogens |
| 01/09/2002 | EP1169334A1 48 human secreted proteins |
| 01/09/2002 | EP1169333A1 49 human secreted proteins |
| 01/09/2002 | EP1169328A2 Avermectin derivatives |
| 01/09/2002 | EP1169327A1 L-arabino-disaccharides of anthracyclines, processes for their preparation, and pharmaceutical compositions containing them |
| 01/09/2002 | EP1169326A1 Process for preparing alendronic acid |
| 01/09/2002 | EP1169323A1 Beta-lactamase inhibiting compounds |
| 01/09/2002 | EP1169322A1 Pyridoxal analogues for vitamin b-6 disorders |
| 01/09/2002 | EP1169321A2 Purine derivatives having phosphodiesterase iv inhibition activity |
| 01/09/2002 | EP1169320A1 Farnesyl transferase inhibitors having a pyrrole structure and process for preparation thereof |
| 01/09/2002 | EP1169319A1 Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
| 01/09/2002 | EP1169317A1 Triarylimidazoles |
| 01/09/2002 | EP1169316A1 Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them |
| 01/09/2002 | EP1169314A1 Crystalline base of citalopram |
| 01/09/2002 | EP1169313A2 1,4-benzothiazepine-1,1-dioxide derivatives substituted by sugar radicals, methods for the production thereof, medicaments containing these compounds and the use thereof |
| 01/09/2002 | EP1169312A2 Glucokinase activators |
| 01/09/2002 | EP1169311A1 Oxazole and thiazole combinatorial libraries |
| 01/09/2002 | EP1169307A1 Pyrimidine compounds with pharmaceutical activity |
| 01/09/2002 | EP1169306A1 Dibenzoazulene derivatives for treating thrombosis, osteoporosis, arteriosclerosis |
| 01/09/2002 | EP1169305A1 Indigoid bisindole derivatives |
| 01/09/2002 | EP1169303A2 Novel aryl-chloro-ethyl ureas |
| 01/09/2002 | EP1169302A1 N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists |
| 01/09/2002 | EP1169301A1 A topical antiandrogen for hair loss and other hyperandrogenic conditions |
| 01/09/2002 | EP1169300A1 Compounds derived from benzoic acid esters, composition containing said compounds and use thereof |
| 01/09/2002 | EP1169298A2 Pharmaceutical compounds |
| 01/09/2002 | EP1169294A2 Pharmaceutical compounds |
| 01/09/2002 | EP1169244A2 Metering valve |
| 01/09/2002 | EP1169065A1 Formulations for detecting asthma |
| 01/09/2002 | EP1169062A2 Heat stable coated colloidal iron oxides |
| 01/09/2002 | EP1169061A1 Combination therapy for treating glaucoma |
| 01/09/2002 | EP1169060A1 Sodium channel blocker compositions and the use thereof |
| 01/09/2002 | EP1169059A1 Docetaxel in combination with rhumab her2 for the treatment of cancers |
| 01/09/2002 | EP1169054A2 Products and methods for treating ptp lar related diseases |
| 01/09/2002 | EP1169049A2 Treatment of myeloma bone disease with proteasomal and nf-kappa-b activity inhibitors |